Top

Published in:

01-08-2020 | Original Article

A vaccine-matching assessment of different genetic variants of serotype O foot-and-mouth disease virus isolated in Ethiopia between 2011 and 2014

Authors: Yeneneh Tesfaye, Fazlurrahman Khan, Martha Yami, Jemma Wadsworth, Nick J. Knowles, Donald P. King, Esayas Gelaye

Published in: Archives of Virology | Issue 8/2020

Abstract

The aim of this study was to assess the vaccine-matching and antigenic properties of foot-and-mouth disease virus (FMDV) isolates collected from Ethiopia between 2011 and 2014. Samples (n = 51) were collected from cattle and pigs with clinical signs consistent with foot-and-mouth disease (FMD) on farms in Debre-Berhan, Debre-Zeit/Bishoftu, Sidamo, Mekelle, and Addis Ababa. Infectious FMDV was isolated using BHK-21 cell cultures from 38 of the 51 field samples (74.5%). All of these FMDV-positive samples were characterized as serotype O, belonging to two East Africa topotypes (EA-3 and EA-4), and their VP1-encoding sequences demonstrated amino acid sequence variability encompassing 27 positions in comparison to the vaccine strain (O/ETH/38/2005) currently provided by the National Veterinary Institute of Ethiopia. One-dimensional virus neutralization test (1 dm VNT) results showed that O/ETH/38/2005 was antigenically matched to 10 of the 16 serotype O viruses. These findings indicate that the O/ETH/38/2005 vaccine strain can provide protection against outbreaks caused by the O/EA-3 topotype, although poorer vaccine-matching results for the O/EA-4 topotype reinforce the importance of using a good-quality vaccine with high coverage in the susceptible herds with supporting post-vaccination serosurveillance to ensure that sufficient antibody titers are generated in the vaccinated animals.

Lewis-Rogers N, McClellan DA, Crandall KA (2008) The evolution of foot-and-mouth disease virus: impacts of recombination and selection. Inf Gen Evol 8(6):786–798. https://doi.org/10.1016/j.meegid.2008.07.009 CrossRef

Ayelet G, Mahapatra M, Gelaye E, Egziabher BG, Rufeal T, Sahle M et al (2009) Genetic characterization of foot-and-mouth disease viruses, Ethiopia, 1981–2007. Emerg Infect Dis 15:1409–1417. https://doi.org/10.3201/eid1509.090091 CrossRefPubMedPubMedCentral

Domingo E, Escarmis C, Baranowski E, Ruiz-Jarabo CM, Carrillo E, Núñez JI, Sobrino F (2003) Evolution of foot-and-mouth disease virus. Virus Res 91(1):47–63CrossRefPubMed

Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F (1989) The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. Nature 337(6209):709–716. https://doi.org/10.1038/337709a337700 CrossRefPubMed

Kasambula L, Belsham GJ, Siegismund HR, Muwanika VB, Ademun-Okurut AR, Masembe C (2012) Serotype identification and VP1 coding sequence analysis of foot-and-mouth disease viruses from outbreaks in eastern and northern Uganda in 2008/9. Transbound Emerg Dis 59(4):323–330. https://doi.org/10.1111/j.1865-1682.2011.01276.x CrossRefPubMed

Sahle M, Venter EH, Dwarka RM, Vosloo W (2004) Molecular epidemiology of serotype O foot-and-mouth disease virus isolated from cattle in Ethiopia between 1979–2001. Onderstepoort J Vet Res 71(2):129–138CrossRefPubMed

Negussie H, Kyule MN, Yami M, Ayelet G, Jenberie S (2011) Outbreak investigations and genetic characterization of foot-and-mouth disease virus in Ethiopia in 2008/2009. Trop Anim Health Prod 43:235–243. https://doi.org/10.1007/s11250-11010-19683-11252 CrossRef

Jemberu WT, Mourits MC, Sahle M, Siraw B, Vernooij JC, Hogeveen H (2016) Epidemiology of foot and mouth disease in Ethiopia: a retrospective analysis of district level outbreaks, 2007–2012. Transbound Emerg Dis 63(6):e246–e259. https://doi.org/10.1111/tbed.12338 CrossRefPubMed

Ayelet G, Soressa M, Sisay T, Belay A, Gelaye E, Jembere S, Skjerve E, Asmare K (2013) FMD virus isolates: the candidate strains for polyvalent vaccine development in Ethiopia. Acta Trop 126:244–248. https://doi.org/10.1016/j.actatropica.2013.1002.1005 CrossRefPubMed

10.

Rweyemamu MM (1984) Antigenic variation in foot-and-mouth disease: studies based on the virus neutralization reaction. J Biol Stand 12(3):323–337. https://doi.org/10.1016/s0092-1157(1084)80013-x CrossRefPubMed

11.

Paton DJ, Valarcher JF, Bergmann I, Matlho OG, Zakharov VM, Palma EL, Thomson GR (2005) Selection of foot and mouth disease vaccine strains—a review. Rev Sci Tech 24(3):981–993CrossRefPubMed

12.

Rweyemamu MM, Hingley PJ (1984) Foot and mouth disease virus strain differentiation: analysis of the serological data. J Biol Stand 12:225–229. https://doi.org/10.1016/s0092-1157(1084)80057-80058 CrossRefPubMed

13.

Sulayeman M, Dawo F, Mammo B, Gizaw D, Shegu D (2018) Isolation, molecular characterization and sero-prevalence study of foot-and-mouth disease virus circulating in central Ethiopia. BMC Vet Res 14(1):110CrossRefPubMedPubMedCentral

14.

Ding Y, Chein J, Zhang J, Zhou L, Ma L, Zhang Y (2013) An overview of control strategy and diagnostic technology for foot-and-mouth disease in China. Virol J 10:78. https://doi.org/10.1186/1743-422X-10-78 CrossRefPubMedPubMedCentral

15.

Gorna K, Houndje E, Romey A, Remly A, Blaise-Boisseau S, Kpodekon M, Saegerman C, Moutou F, Zientara S, Kassimi L (2014) First isolation and molecular characterization of foot-and-mouth disease virus in Benin. Vet Microbiol 171:175–181CrossRefPubMed

16.

Reid SM, Ferris NP, Hutchings GH, Samuel AR, Knowles NJ (2000) Primary diagnosis of foot-and-mouth disease by reverse transcription polymerase chain reaction. J Virol Methods 89:167–176. https://doi.org/10.1016/s0166-0934(1000)00213-00215 CrossRefPubMed

17.

Knowles NJ, Wadsworth J, Bachanek-Bankowska K, King DP (2016) VP1 sequencing protocol for foot and mouth disease virus molecular epidemiology. Rev Sci Tech 35(3):741–755. https://doi.org/10.20506/rst.20535.20503.22565 CrossRefPubMed

18.

Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95–98

19.

Kumar S, Stecher G, Tamura K (2016) MEGA7: molecular evolutionary analysis version 7.0 for bigger datasets. Mol Biol Evol 33(7):1870–1874. https://doi.org/10.1093/molbev/msw054 CrossRefPubMedPubMedCentral

20.

Knowles NJ, Samuel AR (2003) Molecular epidemiology of foot-and-mouth disease virus. Virus Res 91(1):65–80. https://doi.org/10.1016/s0168-1702(1002)00260-00265 CrossRefPubMed

21.

Vosloo W, Bastos O, Sangaré SK, Hargreaves GR, Thomson GR (2002) Review of the status and control of foot and mouth disease in sub-Saharan Africa. Rev Sci Tech 21:437–449CrossRefPubMed

22.

Ramakrishnan M (2016) Determination of 50% endpoint titre using a simple formula. World J Virol 5(2):85–86. https://doi.org/10.5501/wjv.v5.i2.85 CrossRefPubMedPubMedCentral

23.

Das B, Sanyal A, Subramaniam S, Mohapatra J, Pattniak B (2012) Field outbreak strains of serotype O foot-and-mouth disease virus from India with a deletion in the immune dominant βG-βH loop of the VP1 protein. Arch Virol 157:1967–1970. https://doi.org/10.1007/s00705-00012-01380-00701 CrossRefPubMed

24.

Subramaniam S, Mohapatra J, Das B, Sanyal A, Pattnaik B (2015) Genetic and antigenic analysis of foot-and-mouth disease virus serotype O responsible for outbreak in India during 2013. Inf Gen Evol 30:59–64. https://doi.org/10.1016/j.meegid.2014.12.009 CrossRef

25.

Brito BP, Rodriguez LL, Hammond JM, Pinto J, Perez AM (2017) Review of the global distribution of foot-and-mouth disease virus from 2007 to 2014. Transbound Emerg Dis 64(2):316–332. https://doi.org/10.1111/tbed.12373 CrossRefPubMed

26.

Fasina FO, Connell DR, Talabi OA, Lazarus DD, Adeleke GA, Olusanya TP, Hernandez JA (2013) Foot-and-mouth disease virus strains and examination of exposure factors associated with seropositivity of cattle herds in Nigeria during 2007–2009. Prev Vet Med 109(3):334–342CrossRefPubMed

27.

Balinda SN, Sangula AK, Heller R, Muwanika VB, Belsham GJ, Masembe C, Siegismund HR (2010) Diversity and transboundary mobility of serotype O foot-and-mouth disease virus in East Africa: implications for vaccination policies. Inf Gen Evol 10(7):1058–1065. https://doi.org/10.1016/j.meegid.2010.06.017 CrossRef

28.

Mason PW, Grubman MJ, Baxt B (2003) Molecular basis of pathogenesis of FMDV. Virus Res 91(1):9–32. https://doi.org/10.1016/S0168-1702(02)00257-5 CrossRefPubMed

29.

Crowther JR, Farias S, Carpenter WC, Samuel AR (1993) Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J Gen Virol 74(Pt 8):1547–1553. https://doi.org/10.1099/0022-1317-1574-1548-1547 CrossRefPubMed

30.

Kitson JD, McCahon D, Belsham GJ (1990) Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology 179(1):26–34. https://doi.org/10.1016/0042-6822(1090)90269-w CrossRefPubMed

31.

Mahapatra M, Yuvaraj S, Madhanmohan S, Subramaniam M, Pattnaik B, Paton D, Srinivasan V, Paridaa S (2015) Antigenic and genetic comparison of foot-and-mouth disease virus serotype O Indian vaccine strain, O/IND/R2/75 against currently circulating viruses. Vaccine 33:693–700. https://doi.org/10.1016/j.vaccine.2014.11.058 CrossRefPubMedPubMedCentral

32.

Fishbourne E, Ludi A, Wilsden G, Hamblin P, Statham B, Bin-Tarif A, Brocchi E, Grazioli S, Dekker A, Eblé P et al (2017) Efficacy of a high potency O1 Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa. Vaccine 35(20):2761–2765. https://doi.org/10.1016/j.vaccine.2017.02.047 CrossRefPubMed

33.

Paton D, Reeve R, Capozzo A, Ludi A (2019) Estimating the protection afforded by foot-and-mouth disease vaccines in the laboratory. Vaccine 37(37):5515–5524. https://doi.org/10.1016/j.vaccine.2019.5507.5102 CrossRefPubMed

Title: A vaccine-matching assessment of different genetic variants of serotype O foot-and-mouth disease virus isolated in Ethiopia between 2011 and 2014
Authors: Yeneneh Tesfaye
Fazlurrahman Khan
Martha Yami
Jemma Wadsworth
Nick J. Knowles
Donald P. King
Esayas Gelaye
Publication date: 01-08-2020
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 8/2020
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-020-04662-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Editorial: Archives of Virology’s 80th anniversary symposium—6 months later

Generation of a porcine reproductive and respiratory syndrome virus expressing a marker gene inserted between ORF4 and ORF5a

Investigation of Crimean-Congo hemorrhagic fever virus in ruminant species slaughtered in several endemic provinces in Turkey

Sorghum mastrevirus-associated alphasatellites: new geminialphasatellites associated with an African streak mastrevirus infecting wild Poaceae plants on Reunion Island

Complete genome sequence of begonia flower breaking virus, a novel member of the genus Potyvirus

Targeting human cytomegalovirus IE genes by CRISPR/Cas9 nuclease effectively inhibits viral replication and reactivation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials